Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
KEYWORDS: prasugrel, clopidogrel, patients, group, coronary, clinical, assessment, assessment group, committee, myocardial, trial, acute, treatment, acute coronary, intervention

weighing less than 60 kg). The 4 subgroups were: • treated for STEMI and with diagnosed diabetes • treated for STEMI and without diagnosed diabetes • treated for unstable angina or NSTEMI and with diagnosed diabetes • treated for unstable angina or NSTEMI and without diagnosed diabetes. Specific clinical data relating to patients with STEMI, unstable angina or NSTEMI or diabetes in the core clinical cohort were not available from the manufacturer's submission or the most recent publication. In place of these data, the Assessment Group extracted the outcomes from the manufacturer's short-term model for the 4 mutually exclusive subgroups of the core clinical cohort and used these as the initial conditions for surviving patients entering the Assessment Group's long-term state-transition model. 4.2.13 For the long-term projection, the Assessment Group used a modified version of the economic model described in NICE's technology appraisal guidance on clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. This model used data provided by the manufacturer of clopidogrel from the CAPRIE clinical trial, supplemented by data provided by the manufacturer of dipyridamole from the PROFESS clinical trial. The Assessment Group stated that the myocardial infarction subpopulation analysis submitted for NICE's technology appraisal
